Oculis Holding AG Files 2024 Annual Report

Ticker: OCSAW · Form: 20-F · Filed: Mar 11, 2025 · CIK: 1953530

Oculis Holding Ag 20-F Filing Summary
FieldDetail
CompanyOculis Holding Ag (OCSAW)
Form Type20-F
Filed DateMar 11, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: annual-report, financials, sec-filing

TL;DR

Oculis Holding AG dropped its 2024 20-F. Check it for share capital, warrants, and tax loss details.

AI Summary

Oculis Holding AG filed its 20-F for the fiscal year ending December 31, 2024. The filing, submitted on March 11, 2025, provides a comprehensive overview of the company's operations and financial status. Key financial data and disclosures relevant to investors are included, such as information on share capital, warrants, and tax losses.

Why It Matters

This 20-F filing provides investors with crucial financial and operational details for Oculis Holding AG for the 2024 fiscal year, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — As a 20-F filing, it contains detailed financial information, but lacks the immediate market-moving news often found in earnings reports or press releases.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Oculis Holding AG?

Oculis Holding AG is classified under Pharmaceutical Preparations (SIC code 2834).

When was the 20-F filing submitted to the SEC?

The filing was submitted on March 11, 2025.

What is the company's fiscal year end?

The company's fiscal year ends on December 31st.

What types of share capital are mentioned in the filing?

The filing mentions Conditional Share Capital for Earnout Options and Conditional Share Capital in Connection with Employee Benefit Plans.

Does the filing mention any offering programs?

Yes, the filing references an 'At The Market Offering Program' dated May 8, 2024.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on March 11, 2025 regarding Oculis Holding AG (OCSAW).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing